Evidence map›Paper›PMID 32460818›Full record

ArticleTrials2020

Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial.

Caroline Forde, Ronan McMullan, Mike Clarke, Richard H Wilson, Ruth Plummer, Margaret Grayson, Cliona McDowell, Ashley Agus, Annmarie Doran, Danny F McAuley and 5 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 1 country.

Caroline FordeCentre for Cancer Research and Cell Biology, Queen's University Belfast, Lisburn Road, Belfast, BT9 7AE, UK. cforde01@qub.ac.uk.
Ronan McMullanCentre for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Mike ClarkeNorthern Ireland Methodology Hub, Queen's University Belfast, Belfast, UK.
Richard H WilsonTranslational Research Centre, University of Glasgow, Glasgow, UK.
Ruth PlummerNorthern Institute for Cancer Research, Newcastle University, Newcastle, UK.
Margaret GraysonNorthern Ireland Cancer Research Consumer Forum, Belfast, UK.
Cliona McDowellNorthern Ireland Clinical Trials Unit, Belfast Health and Social Care Trust, Belfast, UK.
Ashley AgusNorthern Ireland Clinical Trials Unit, Belfast Health and Social Care Trust, Belfast, UK.
Annmarie DoranNorthern Ireland Clinical Trials Unit, Belfast Health and Social Care Trust, Belfast, UK.
Danny F McAuleyThe Wellcome Wolfson Institute for Experimental Medicine, Queens University Belfast, Belfast, UK.
Anne L ThomasLeicester Cancer Research Centre, Leicester, UK.
Rosemary A BarnesCardiff University School of Medicine, Cardiff, UK.
Richard AdamsCardiff University and Velindre NHS Trust, Cardiff, UK.
Ian ChauThe Royal Marsden NHS Foundation Trust, London, UK.
Vicky CoyleCentre for Cancer Research and Cell Biology, Queen's University Belfast, Lisburn Road, Belfast, BT9 7AE, UK.
Queen's University Belfast · GBBelfast Health and Social Care Trust · GBCardiff University · GBNewcastle University · GBNIHR Leicester Biomedical Research Centre · GBRoyal Marsden NHS Foundation Trust · GBThe Northern Ireland Cancer Centre · GBUniversity of Glasgow · GB

Funding

Cancer Research UK 25350Department of Health 13/140/05Medical Research Council G0901530
6 · The paper itself

Abstract

backgroundNeutropenic sepsis remains a common treatment complication for patients receiving systemic anti-cancer treatment. The UK National Institute for Health and Care Excellence have not recommended switching from empirical intravenous antibiotics to oral antibiotics within 48 h for patients assessed as low risk for septic complications because of uncertainty about whether this would achieve comparable outcomes to using intravenous antibiotics for longer. The UK National Institute for Health Research funded the EASI-SWITCH trial to tackle this uncertainty.

methodsThe trial is a pragmatic, randomised, non-inferiority trial that aims to establish the clinical and cost-effectiveness of early switching from intravenous to oral antibiotics in cancer patients with low-risk neutropenic sepsis. Patients ≥ 16 years, receiving systemic anti-cancer treatment (acute leukaemics/stem cell transplants excluded), with a temperature of > 38 °C, neutrophil count ≤ 1.0 × 10 DISCUSSION: If the trial demonstrates non-inferiority of early switching to oral antibiotics, with potential benefits for patient quality of life and resource savings, this finding will have significant implications for the routine clinical management of those with low-risk neutropenic sepsis.

trial registrationISRCTN: 84288963. Registered on the 1 July 2015. https://doi.org/10.1186/ISRCTN84288963. EudraCT: 2015-002830-35.

Indexed as

Administration, IntravenousAdministration, OralAmoxicillin-Potassium Clavulanate CombinationAnti-Bacterial AgentsCiprofloxacinCost-Benefit AnalysisDrug Administration ScheduleEquivalence Trials as TopicHumansMeropenemMulticenter Studies as TopicNeoplasmsNeutropeniaPiperacillinPragmatic Clinical Trials as TopicQuality of LifeAmoxicillin-Potassium Clavulanate CombinationAnti-Bacterial AgentsCiprofloxacinMeropenemPiperacillinTazobactamCancerLow riskNeutropenic sepsisNon-inferiorityOral antibioticsRandomised controlled trial

Identifiers

PMID32460818
PMCPMC7251886
OpenAlexW3032563905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.